Dibutylone (bk-DMBDB)
Dibutylone (bk-DMBDB) is a methylenedioxy synthetic cathinone stimulant-entactogen that appeared as a designer replacement for butylone and other banned cathinones. Human pharmacology is essentially unknown, with only forensic and case-report data.
01 Overview
Dibutylone is a dimethylated, methylenedioxy cathinone related structurally to butylone and pentylone. It circulated in research-chemical and "bath salt" markets, often mislabelled, and is reported to combine stimulant drive with a weak entactogenic quality.
No controlled human studies exist. It is known through seized-material analysis and intoxication case reports, and has been scheduled in a number of jurisdictions as novel cathinones were successively banned.
02 Mechanism
Presumed monoamine releaser and reuptake inhibitor with mixed dopaminergic and serotonergic activity from its methylenedioxy ring, based on close structural analogues.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 25–70 mg | Insufflated | Harsh; faster onset. |
| Light | 30–75 mg | Oral | Anecdotal only; poorly characterised. |
| Common | 75–150 mg | Oral | User-reported range. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| StimulationEnergy and wakefulness with a stimulant emphasis. | Anecdotal | ||
| Mild entactogenic effectsSome warmth and sociability, weaker than butylone. | Anecdotal | ||
| Increased sociabilityTalkativeness and disinhibition. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Compulsive redosingShort, underwhelming effects encourage repeated dosing. | Moderate | Common | Anecdotal | |
| ComedownAnxiety, fatigue and insomnia after use. | Moderate | Near-universal | Anecdotal | |
| Cardiovascular strainTachycardia, hypertension and palpitations reported. | Severe | Common | Observational | |
| Unknown neurotoxicityLong-term neurotoxic potential unstudied. | Severe | Unknown | Unconfirmed |